CMRX - Earnings call transcript Q2 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, ladies and gentlemen, and welcome to the Chimerix Second Quarter 2022 Earnings Conference Call. I would now like to introduce you to your host for today's call, Michelle LaSpaluto, Vice President of Strategic Planning and Investor Relations at Chimerix. Please proceed.

Michelle LaSpaluto

Thank you and good morning everyone. This afternoon we issue a press release on our second quarter operating update.

press our this the section access website. can release Investors in of You today's and Josh Financial our Mike me Technology Officer, call, With on our and President Mike Chief Medical Chief Allen Randall Lanier; Officer, of Sherman; Officer, Chief Melemed; Business Chief Imipridones, and Officer Andriole; Science Allen. Chief Officer, Executive

Act within These the of and Securities today's call on Before I like would made a materially refer the of subject Private Chief Sherman. are we these more forward-looking from and other differ cause uncertainties the to forward-looking this Executive to XXXX referred statements other the risks statements to statements. begin, and Litigation uncertainties, to actual of uncertainties. factors Mike to could in Reform I turn remind risks with Please filings you President to that At and would and meaning like include risks the our and and Officer, for complete results our time, call disclosure those SEC to over the factors.

Mike Sherman

busy immediately couple and to decision, biodefense to because in of matter and contracts everyone. been us product a was we've the million our revenue over of were ago and July, international of somewhat without of In the aggregate. our progress treatment a Thanks two this advantage joining with Because agreements of of few that TEMBEXA years we me TEMBEXA products start past $XX contract, right in only possible TEMBEXA. today. I'll for milestone details the space. so We've at a courses marked risk to opportunity take significant made able own afternoon, completing get we first decision months, made Good shipping a XXX,XXX let days. manufacture the we recording covered by This of atypical

that respond so thoughtful examples. and are on BARDA place. you're and new it Chimerix, the contracts, and agreement relates is the looking creating as monkeypox have great into assess will we and The considerations TEMBEXA to the near-term also mentioned once at to manufacture sales stockpile isolate execution outbreak product same us to place address some delivering our are both meantime, needs. risk for If immediately to to U.S. the decision those these Chimerix's urgently. BARDA capital we've been We have introduced international to the recorded In satisfied in previously position

including either the the of a in of approved potentially while spreads have aware mutates against FDA as humans multiple be is fact into control options are was orthopoxviruses leading disease with FDA the may matter and post-approval of commented performed been on monkeypox potential unknowns for approved physicians manuscript. data infectious there We're that TEMBEXA that smallpox, monkeypox. lot still You on of the additional And The studies data. resistant more no preclinical to generate randomized strains. support smallpox. with with for antivirals their The activity TEMBEXA potential does virus in working

third ONCXXX. probability a announce study let to have multiple Phase I'll comes patients. design and I data to compared data. few generated KOLs population drug's should Phase the the to of of this down differentiated in success. differentiate We've studies Allen design to without drugs and X highly trial high pleased today other Phase is in advance X ways about Phase of geographies X action success It Let our details, we let the ONCXXX, study in been likelihood me a now the to efficiently. into have that a this X go action design but Phase really make KXXM broader from of of glioblastoma was This space. across that with and the achieve studies me space a disciplines points performed worked study that's upfront. turn the this advanced with X of the the hand HX that to The this to details other in in most it circumstance really is first which note

source the same ONCXXX that genetically reliable Phase previous the focus Phase diagnostic KXXM. on to those did X. distinguish is have failed For benchmarks. which homogeneous Many agent combinations historical isolated with in X those X, conducted X patients used. can been Phase then a to population already contrast, we We compared that critical. also in And washout can that Phase like of the on population in carefully drug like The effects. or nearly with universally data, PFS of advance it the point of HX the X activity Phase single periods on They that relied time rare our associated isolation have Phase endpoints are also data. based data we've patients was same to of With X mutation patient drug target, agent was methods in have activity targeted the specified adequate were identify with studies single used tools in

company method short and developed as of rate response Importantly, some we've rigorous shortcomings response criteria, using the XX prior the This to measured tumor criteria. RANO – most of such was MacDonald measures standard. address

can false studies We data data previously safety was at lock It's anti-angiogenic Avastin, important noted years. responders ongoing critically were generated prior and and response response by risk were the between was to reveal expected. call work XX% if alive latest I'll not all we've safety attractive XXX the to over a The rate as and central There's using efficacy which very as review the Phase our that absence turn our the to over assessment multiple particularly efficacy like robust at Last use by completed XX% yield demonstrates assessments, of to Our data consistency increased to assessment relative more also X two assessment. or those X failed association criteria. of the as success at well stringent cohorts. details improvement confidence evaluated ONCXXX association action the in the who earlier compiling two convincing. translate in for patients with summary have is to as consistency XX to the performance to of patients just responses did more historically share ONCXXX. also profile strengthen durability Allen data response the steroid than were drugs. internal happy about of which none a I'm a status. imaging we years overall this related on of safety in the two data using to reported of a done finally, benefit relapse clear is achieve blinded years that data response confound for Phase setting patient of complimented alive progression a The clinically from less fall And the other independent endpoints drugs hit findings those say the and of Allen? RANO safety striking. now reduction survival an the results meaningful and study, across an a also alive in in

Allen Melemed

for an international OS Monitoring over and the We're Karnofsky this of OS by U.S. to who Key expecting inclusion fluid year mutation. randomized, central sites tasks, a North half KXXM will Treatment I'm interim randomization. survival. PFS is which time The by throughout Committee into perform sites assessed glioma in placebo. ACTION dosing will excited of the whose Europe frequencies with primary pontine up are our be tumor of XXX and endpoint criteria an ONCXXX study patients PFS. therapy. harbors sighting glioma or be assessment. to the have ordinary the followed will a to and Thank The will is milligram year. place randomized XX dissemination. at study. occur alpha controlled study HX of XXX performance ability be diagnosed by two receive weekly final of go cerebral to The later at greater of study details study The in once of study X twice a XXX to newly review. had presence of alpha spinal of double-blind, analysis ONCXXX approximately you, patients' Lansky Participants with at activate continue Independent than survival for a Asia-Pacific. and following primary sites actions evidence next completion HGG is evaluate patients, will both briefly left RANO Phase placebo-controlled select using Mike. or progression-free disease will of a one first mental or also diffuse or overall the the equal The intrinsic America, to spread radiation efficacy status, assessments of diffuse take of enroll in blinded or Data measure two tumor time spinal multicenter points: must performed and will three final independent control

X.XX The on respond X an data on for Phase point. study time XXXX less KPS survival to the The one. disease increase equal versus first control interim [indiscernible] of the builds of data should the The increasing an each line would will for perform XX. to patients group analysis study in the an one in with has on limiting bulk These Independent factors including than for greater that well to being on X.XX earlier XXXX. ratio as greater and at finite the moving to patients and as patients comparison each with free XX% nearly anticipated overall hazard with assumed study likelihood study to likely findings patients progression survival. power with time include that for design

All better response the were set. with associated data factors Phase X in of these

there’s wrap standard therapy. radiation natural In of identify a with of at will to of The time an time a tests. be completion care design includes diagnosis enrollment. addition, render KXXM of study part elements, as mutation gap should initial between patients an of the available diagnosis the and This initial presence identified as support widely the HX has six-week a which wider number

In one in addition, twice to a placebo. of this patients to KOLs excitement received globally are study. participate on likely receive as from numerous We

clinical patient we pushed FDA push keenly as for multiple ONCXXX was of mainly is in dose we’ve in single randomized and analysis that analysis, trials Noting new in on of an and previous this guidance schedule target indications, successful with treatment that generally patients X% additional on questions been efficacy evolving, included financial Grade to [ph] meantime, upside study vomiting. or X.X% ONCXXX tolerated events date more to five Phase neutrophil recent or events Grade addition one neutropenia FDA the embolism safety based study probability discussions are speak in increased well efficacy Adverse Phase data results. in adults. schedule, of counts common at drug. dose the discontinuation X revisit this X patient, than patient. I at reported decreased to were generally in and higher These to this X to Mike headache, turn with in fatigue we towards further of have now Phase a the This in or added over our trial FDA adverse were quarter registration, development has Most data experienced underway. approval listening study three Chimerix. the in safety patients were has population And characterization expectations event increasing of our the related X programs the dose related similar in enthusiasm plan fatigue, and a Lastly, been reported, risk occurred includes emergent, oncology adverse and drug leading we’ve and our which pediatric events of reported to In With a with only reduction study. hand, that with additional fourth we patients, drug the updating and incorporated an patients. based A With that soon already of data this one this event hypersensitivity that, trials. were In benefit interruption. this were in – With treatment those X.X%. to The Only related XXX the one this robust safety this events year. the been performed data accelerate in pulmonary of a the of we’ve to adverse Andriole analysis nausea reported that ONCXXX X. better X in

Mike Andriole

to we’re and good overview potential Allen, I for for everyone. Thanks, just on study its the commercial action wanted why outcome, rationale afternoon, ONCXXX. Allen’s a market make and optimistic comments of With about the few

unmet particularly among worst among of lethal of and in diffuse particular and all gliomas KXXM-mutants aware KXXM-mutants already HX for the are needs The highest what a a of you new are HX of form is As broadly cancer glioma in in poor need are brain oncology. most the prognosis. therapies is unmet

As indicates And awareness of research it following KXXM-mutants ACTION the across the agent markets. for sites that market XXX in relates to the ONCXXX, of study our up unaided this is already high. HX the major to participation

landscape is This We expect top to should translate this successful, adoption this that ACTION markets. of agent association likely aided study to attractive. the be HX prescribing the be rapid If therapy is nearly adoption the by competitive we among neuro quite will of oncologists. awareness KXXM-mutations major expect ubiquitous in a will

years. other $XXX industry launches million. oncology here a relatively Phase Phase These ONCXXX commercial likely annual unique in underperforming have revenue opportunity there mutation. where low view to a market continue or of this we've worldwide of comfortably dynamics Specifically, commercial examples as risk in the X exceed recent viewed in as we're this any should targeting that programs and aware been Consequently, several in the X make not

of two As and totally million third least in including nearly approximately international been of million. earlier past a all that recently, Mike On pro basis, $XX we'll additional million the $XX at when $XX forma this announced this product realize have mentioned revenue. procurement delivered would at we July, cash quarter. We've TEMBEXA revenue of nearly the June end contracts,

TEMBEXA waiting As it conditions. the of pending Emergent HSR transaction in satisfied to late to that the the sale one of for expired July, key relates period closing the

the BARDA the know the public that key the are To end, conditions of WHO a when to emergency parties we has sale remaining possible. with BARDA to BARDA as two to another of we the the position health a with I closing the execution finalize the other the will ordinary cash recent of the market the how both cash eager are interim, Chimerix current pipeline programs by operate well the declaration and HHS Certainly, of contract have addition pre-novation details our reasonably in outbreak expected as soon that counterparts as are and both term contract business and from agreement. continue to as final the update Emergent. TEMBEXA, the be of Chimerix In other provide concern the of course in the influenced to investors monkeybox our we expects and approaching executed to expeditiously on With to work generated diluted financing. positioned advance of procurement contract near between finalization will at a this are agreement agreement BARDA’s and ACTION BARDA without we. The can. approval study

million XXXX. to per $XX.X diluted per statement the period our the of to closing And basic moving and for operations. administrative call $X.XX XXXX loss or Now Mike? share and $X.X of diluted $XX second of or increased quarter Mike now second of compared quarter Research increased million second for second XXXX. basic to compared $XX.X the period reported million with quarter the a to the company for of for of I'll related quarter expenses The share net and with a and to Sherman million back in XXXX, $XX.X of ongoing The ONCXXX. $X.X XXXX, development for remarks. million for net turn the $X.XX loss the the compared same of to XXXX. overview, this to expenses in million increase driver main development General is in same that

Mike Sherman

Thanks, Mike.

open for it comes with questions, President the stages Jordan across Christopher like pharma a I'd of take of Vice to minute our I as welcome Christopher to development. up Before to product to XX all years over team Affairs. experience of us Regulatory

of in FDA it's pleasure as His led of Pluvicto and endo had the PSMA-XXX where the the and continue Brianna, team have of submission recently known. EMA management regulatory Some approval strategy the now of of field the and for he execution the regulatory a with or knowledge our and Christopher oncology at I'll the Novartis, working site we be addition over great development you, turn to oncology pipeline. our it record call navigating team will questions. processes do that With complicated to track as open of

Operator

Thank Jefferies. first you. [Operator Your will from with Maury Raycroft come Instructions] question

now is line Your open.

Maury Raycroft

getting the X questions Hi, and design. my on congrats thanks taking Phase for

the For you events. could initial data file two or final either independent XXX assessments then be at the the If X, XXX XXX at XXX approval? to events and Phase interim events, committee interim monitoring of at for XXX OS have then and by successful, assessments enough

Mike Sherman

those and pretty you'll the hand, got – such submission be data – Yes, are response designed at to We overall and expect statistical those advantages. endpoints of significance at endpoints with regulatory significant approval. you've have basis those PFS with rate a in early those would that hand in survival

Maury Raycroft

talk about dosing in Got per it. can twice week the moving seen data that the and And then more clinical twice a you've X? supports the also dosing you rationale Phase week what prior the into for

Mike Sherman

it over to experience as in I for share some Yes. well both of including prior trials. as just Josh turn it the Allen that to rationale and we've may directly had the with

Allen Melemed

this Allen. is I'll Yes, start.

has have We and evaluated shown safe been that effect have an in studies. dosing regimen this a been twice weekly several

we seen wanted helps for situation of addressed current we more comments. to the This I'll move this from to get FDA have that We [indiscernible] the far and seen in address challenge have any patient try have reasons want and is shots maximize to effect is that the you dosing part, Josh dose. a opportunity with have haven't pass also to two and and the from know regimen. but also we've we additional do dose this to to with on One we goal, for we study what want to intense safety places think essentially the of forward where you really optimization even regarding it you've so a on two the on ONCXXX seen

Josh Allen

of rationale just little and spot in that an preclinical towards really Sure. prolonged increased with effect. showing to leading the exposure same of speaking from is really that maximal efficacy incubation vitro bit concentration the sweet to the This comes to ONCXXX hours XX can time, be a with findings, a

So these we're on a with achieving giving there, is day consecutive those that the to we that just duration that the therapeutic might a dose thinking unlocking second current getting be in can models. dose an based on tumors if an increase into day brain concentrations. by a extra prolong And efficacy for key

So experience in with to safety that Allen is clinic in to what that. us combination that the incorporate the leads spoke

Maury Raycroft

Got it…

Mike Sherman

Maury. notion you that thing, a trial, X:X I'll – single schedule. that randomization go encourage The if would need add anyway, an were it other one enrollment this to in a to to

you of in and just here bit aggregate. And benefit a that higher kind get little X:X with so,

good it's enroll. use still the a to success encourage get and So of for on think order another I statistical goal shot power in to patients

Maury Raycroft

with that's if and helpful. additional communicated X data if still on in just approval an last Got And the Phase that's they wondering the it. – question supporting for data, accelerated table. communications path Yes, me, whether all maybe on FDA on based if if

Mike Sherman

to that the bit that in we the were Yes. our X discussed spring conversation after strong and for little focus in feedback this a without safety a Phase this getting delayed their on risk earlier essentially benefit at trial limited this We data with last make hand assessment. – call, additional – moving knowing case a our with ability we as we

which have So now additional really exactly able plays dataset, expected, that back we out as we to we'll go them. be safety this to

in Phase year. here the beyond really revisit haven't meantime, that this the So, We'll that we later pushed trial. conversation X

Maury Raycroft

Got it.

my taking questions. Okay. Thanks for

Mike Sherman

Maury. Thanks,

Operator

with question Your comes from Thome Cowen. Joseph next

now is open. line Your

Joseph Thome

first in radiation. can afternoon timeframe after administrating the Good timeframe the Maybe in helpful. thank the on X, there. just a our this one analysis of the Is Hi, X population? maybe would the to Phase for patients that there with study? Phase That completion taking and you shortly questions. ONCXXX post-radiation And mandated that's saw you compare you're ONCXXX be

Mike Sherman

answer Sure. I'll one. let Allen that

Allen Melemed

looking at there a couple you're this. So is ways

One radiation reasons initially when allowing they're the of starting diagnosed we're to the the process and way, done this patients we've then therapy. start screening

which of grab weeks of want I post have initial patient. I eight where correct a sorry, ask to actually clarify and post get post specific exact this, to have me. the Josh time. they the you should So you plenty six front but There my can to which randomized, time timeframe, you don't diagnosis, is radiation, radiation, that Josh believe I in not – I'm be

Josh Allen

of six two three Yes, that to sure. months, in relapse And analysis We'll study. to was enroll post-radiations weeks contrasts and prior than efficacy that the for washout range setting the this the there. more period

perhaps So substantially them think shot is which to prolonged and of give response. we better moving this up therapy having will study closer a at patients duration radiotherapy, better

Joseph Thome

Okay, you. does then TEMBEXA limit a finalized, any to EBS hit forward or you should closing the needs is to additional part kind that of going the perfect. that much. be maybe event? associated to you deal And there ex-U.S. when substantial have contract then time like very on be a over BARDA with the revenues second jumping have And markets? we Thank XXXX of anticipate Thank key

Mike Sherman

hit Mike let those questions. two I'll

Mike Andriole

Joe. It's Yes, XXth in September available there's that for That's an internationally. outside parties, international there discussions we then that to as with have the continue relates both date to parties in And it opportunity, agreement. agreement.

emergencies declaration sort the public in by those certainly is health I continues activate of the the WHO of interest to conversations. think

of conversations ones ahead. in end turn weeks very able we quickly. We'll were to were around the the that to those continue at into entered June we that contracts the So certainly have

Joseph Thome

Perfect. Thank you much. very

Operator

H.C. question with comes Ed from Your White next Wainwright.

now Your is line open.

Ed White

my questions. Thanks evening. for taking Good

accelerated somewhat in X a two set Just tamper using FDA approval? have accelerated the schedules circling Phase approval? different back to And dosing approval, the with the the expectations study, – meeting the you for regarding does date yet accelerated potential for

Mike Sherman

this. the is that the been to at as a preparing add others of let well having in place would just an for and I'll We're is the the and has now the running materials accelerated suggest wants that would that that – part I approval accelerated basis meeting just really and needs Yes, be an completed. safety an study from big time to up approval. the see considering what would taken advanced regulators FDA be and action on dataset in

that relative more So the that insufficient approval If higher actually would were be a but would I some an could review, we safety exploring provide simplifies potential then from comfort. because we're think your efficacious impact exploring also more accelerated not potentially that it's actually lower – that think the your doses, might some I it's that lowering approval an dose regimen. their dose. It in obviously of arise potential accelerated actually issues not effective lower commercial dose or if problematic to

having was much this their conversation. robust a guidance And frankly impacts consideration that optimization to would as assessment that dose consistent be don't survival that way, be So confirm of with their it having full for supportive relates to certainty anyway. – a think more in really overall gets just I think think robust required with approval them a fact and of I going it to design negative in I a around

Allen Melemed

Hi, Mike. Can here? is I add This Allen.

we back. FDA the actually from into approval feedback [ph] received I and this years goes of have back received think the part

back things the have optimization evolved in So situation then in wasn't FDA. really dose

they’ve So again, more according is if optimization that. focused on what of you said, go dose aspect to the X Phase often

have also high significant So I I to with Mike This that reasons it. need have is unmet population discuss think, do with very agree need. the still we

Ed White

regarding data then TEMBEXA monkeypox? and in preclinical studies or just And review perhaps been thoughts outside just monkeypox Emergent for little either you any on in detail, bit you your if pursuing a by monkeypox, could on due U.S. government have more and you purchases the monkeypox to thanks. potential Okay, approached regarding the

Mike Sherman

monkeypox, the approval never it given relates outside context, think to result Those in referenced smallpox. I accelerated parties in the – directly as I’ll U.S. conversations Maybe maybe as the that of were add a the likely with although

over terms an basis turn said, just of of in active use couple for be a Mike Maybe that monkeypox, there and As lot safe of in to some pretty knowing a population. I’ll ongoing. those Randall, comments to agent believe is the there it that are compelling are this treatments to for unknowns conversations TEMBEXA make

Randall Lanier

guess, Sure. we that in I’ll tested. sensitive It’s the second sensitive the and than we’ve four for twice orthopoxvirus just times ever sensitive that I mousepox that rabbitpox for start, variola, the times with and approval. Mike, than XX so TEMBEXA use say about is more virus most as sensitive more vitro as monkeypox we to about virus use approval about

there’s monkeypox standpoint, vitro responsive in reason believe an from to every So that would highly be to TEMBEXA.

We also two animal models. have

TEMBEXA, sort prairie of with mice, it one protection [ph] monkeypox infection a dogs novelize and was faster. dogs like then protection, it TEMBEXA but from turned in XXX% much intermediate prairie in virus them that of a actually which monkeys One showed out where

receiving was ALT TEMBEXA caused is UK XXX discontinued. reason humans, the responses all intermediate TEMBEXA that where fully the kind XXX ALT reasons placebo on in to of manuscript patients the were published X% – So actually that’s the did patients well the that With And obviously, patients They cases fully. instead ALT monkeypox were the three responded patients exposure with elevations transient of cases there. which TEMBEXA human. we the for TEMBEXA the of effects. that But arm the add fully virologic to paper TEMBEXA and very ignored respect within all in all in Prairie all we three don’t about clear drug elevations, the was be placebo dogs to the of to three have did But responded that fairly of regard And the There that I elevations that recipients understand. the was just should the X% recipients arm. FDA negative was there’s recover. virus data, and saw where of versus XX% TEMBEXA

for So this should all of work well the data quite drug that suggests monkeypox.

Ed White

great. for Thanks taking my questions. Okay,

Randall Lanier

Ed. Thanks,

Operator

comes Jones question Soumit next Roy Your with Research. from

is now open. Your line

Soumit Roy

mostly everyone, the possibly regimen Hi, glioma can A ACTION the those chemo better us days placebo thoughts? temozolomide as than and the second and a or the remind on on line relapsed/refractory on progress. treatment trial, arm congratulations patients? choice for it also and ACTION, rather from a or prior Phase Allen, have all if were good the control immediate what to been Was would’ve just the you question a X, physician’s any radiation

Allen Melemed

Yes.

go of to important going then choice standard radiation wait trial Patients control think Phase it’s in until in care. arm. And I’m radiation receive the the to they first the no progressive and therapy, typically disease. really there the I to X the of therapy the is So post control note

So to Typically we will disease. builds an time think the going of actually ideal this some on the saw this. smaller have study factors that in It increase we also this success. the on of you’re little a probability Phase trial the is X to setting,

the be we to XXs. include score lower and then going on are going You’re include KPS longer, the to and in therapy

these since studies. he ask of Josh this we found was I’m factors technical in X to from the was who think population. in go success prior, to doing he increase going the kind of these the one through initially do what So our Phase probability Josh? trials

Josh Allen

of as I Hi. Yes. and therapies have that prior experience, XX than radiation waited days obviously more on and patients noted comments. regards recurred earlier these the recurring all to With

Even of in saw glioma, to that paucity symptomatic getting to prior Other other addition bevacizumab population to for to KXXM-mutant therapies, though benefit relief just these and [indiscernible]. tended agents. saw the included not we to exposure adult chemotherapy the ONCXXX terms have subsets that, given in within patients known particularly is therapies of In include edema temozolomide. of HX of additional still

So of mixture we’ve we’re [indiscernible]. the in here, to will just chemotherapies earlier, we’ve really chemotherapy. benefit our a those And to of likelihood therapy we’ve hopeful a couple as times noted exposure earlier been that prior increase been line patients

Soumit Roy

the pre-IND in for Thank Got question you what ONCXXX, last just this one the or timeline are it. curious you that. bring of thinking on on drug to And clinic?

Mike Sherman

been study a the has has the and accelerating our and in on by The is being one be NIH really two to evaluated ONCXXX. been drug that we Yes, focus pediatric studies, another mentioned on fair sponsored adult adult. of

dose of into indication therapeutic through sort year. that on what would get closer that And so we pursue report window we we as get of be But we end to escalating expect program, we’ll readout I that. here would that for a an that separately into able selection the are data next to would be expect to

the development same ONCXXX that the even targets of drug though opportunities talked we’ve ONCXXX within the that past in One up oncology. is terms are in as there’s things opens the for of different about

And certain so we would expect to indications with ONCXXX. non-overlapping pursue initially

Soumit Roy

you the it. much taking Thank question. Got so for

Mike Sherman

Thank you.

Operator

the time. at Sherman. over now I questions turn will no further are There this call Mike to back

Mike Sherman

joining the And again, Thanks, Have updates, to Thank good for call. forward progress everyone evening. you. thanks We the BARDA Brianna. a contract. look particularly on of the next the

Operator

This conference concludes today’s call.

You may disconnect. now

Chimerix (CMRX) 9 Aug 222022 Q2 Earnings call transcript